美国子宫内膜异位症治疗市场规模、份额、趋势分析报告，按治疗类型、药物类别、给药途径、分销管道、细分预测，2025-2030 年

美国子宫内膜异位症治疗市场的成长与趋势

根据Grand View Research, Inc.的最新报告，美国子宫内膜异位症治疗市场规模预计到2030年将达到12.841亿美元，2025年至2030年期间的复合年增长率为11.86%。

子宫内膜异位症的特征是子宫外存在类似子宫内膜的组织，越来越被认为是严重的健康问题。据约翰霍普金斯医学院称，这种疾病影响了美国25至40岁女性的2％至10％，给患者带来身体、精神和经济负担，常常降低他们的生活品质并限制他们参与日常生活。

子宫内膜异位症的盛行率不断上升，推动了对创新治疗方法的需求，以满足未满足的医疗需求。製药公司正积极开发标靶治疗，以改善子宫内膜异位症患者的治疗效果。例如，辉瑞和 Myovant Sciences 于 2022 年 8 月实现了一个重要里程碑，FDA核准了Myfenvry，这是一种旨在治疗闭经女性中度至重度疼痛的新型口服疗法。此项核准体现了该行业致力于解决子宫内膜异位症患者面临的独特挑战。

强调早期诊断和及时治疗的公众意识宣传活动也对市场成长做出了重大贡献。纽约州卫生部每年举办的子宫内膜异位症宣传月等活动，以及子宫内膜异位症基金会等组织的宣传活动，旨在教育公众并减少人们对这种疾病的耻辱感。这些宣传活动强调了慢性疼痛、不孕症和精神健康问题等疾病的严重影响，并鼓励患者寻求有效的治疗。

研发方面的投资正在加速市场扩张。政府、私人公司和製药公司正在投入大量资源来推动子宫内膜异位症的治疗。值得注意的例子包括 Sunstone Life Science Ventures，该公司于 2019 年向 Forendo Pharma 投资 559 万美元，用于开发新型治疗方法，以及 AIMA Laboratories，该公司于 2022 年融资 4.685 亿美元，用于创新用于资金筹措子宫内膜异位症的居家血液检测技术。这些努力凸显了尖端治疗和诊断进步所推动的市场成长潜力。

儘管取得了进展，但市场仍面临挑战。非处方药（OTC）和学名药的盛行正在抑製品牌药的成长。注重成本的患者通常会选择非处方药，例如学名药和非类固醇抗发炎药（例如阿斯匹灵、萘普生、Ibuprofen），来控制子宫内膜异位症相关的疼痛和发炎。这些方便且价格合理的替代疗法通常用于治疗较轻微的症状，这限制了更先进的荷尔蒙疗法和外科手术的可用性。

总体而言，由于人们对该疾病的认识不断提高、治疗方案的创新和研发投入的加大，子宫内膜异位症市场正处于关键的十字路口。儘管定价问题和学名药竞争仍然是挑战，但市场趋势为相关人员提供了解决未满足需求和改善病患生活的重要机会。

美国子宫内膜异位症治疗市场亮点

• 根据治疗类型，荷尔蒙疗法领域将在 2024 年占据市场最大收入份额，达到 78.51%。荷尔蒙疗法是治疗子宫内膜异位症症状（尤其是疼痛和发炎）最有效、应用最广泛的治疗方法，在市场上占据主导地位。
• 依药物类别划分，促性腺激素分泌释放激素 (GnRH) 疗法占据市场主导地位，2024 年销售额份额最大，为 51.33%。 GnRH 疗法因其针对性的作用机制，可以抑制子宫内膜生长，具有良好的疗效和依从性，因而受到高度青睐。
• 根据给药途径，口服药物占市场主导地位，2024 年销售额份额最大，为 49.14%。口服给药因其方便、易用和患者依从性而成为子宫内膜异位症治疗的主要方式。
• 依分销通路划分，零售药局部门占据市场主导地位，2024 年销售额份额最大，为 60.99%。零售药局因其广泛的可及性和在配发处方笺药方面发挥的作用而成为主要的分销管道，尤其是针对子宫内膜异位症等慢性病的处方药。

目录

第 1 章美国子宫内膜异位症治疗市场：调查方法与范围

第 2 章美国子宫内膜异位症治疗市场：执行摘要

• 美国子宫内膜异位症治疗市场：市场展望
• 美国子宫内膜异位症治疗市场：市场区隔
• 美国子宫内膜异位症治疗市场：竞争考察

第三章美国子宫内膜异位症治疗市场：产业展望

• 美国子宫内膜异位症治疗市场的系统展望
• 使用者观点分析
• 渗透和成长前景规划
• 监管和报销框架
• 市场动态
• 美国子宫内膜异位症治疗市场分析工具
• 美国子宫内膜异位症治疗市场管道分析
• 美国子宫内膜异位症治疗市场未满足需求分析

第 4 章美国子宫内膜异位症治疗市场：竞争格局

• 主要市场参与企业的近期趋势和影响分析
• 公司分类
• 供应商概况
• 上市公司
• 私人公司

第 5 章美国子宫内膜异位症治疗市场：治疗类型的商业分析

• 美国子宫内膜异位症治疗市场：治疗类型变化分析

第六章美国子宫内膜异位症治疗市场：给药途径业务分析

• 美国子宫内膜异位症治疗市场：给药途径变化分析

第七章美国子宫内膜异位症治疗市场：药物类别商业分析

• 美国子宫内膜异位症治疗市场：药物类别变化分析

第 8 章美国子宫内膜异位症治疗市场：通路业务分析

• 美国子宫内膜异位症治疗市场：通路变化分析

第九章美国子宫内膜异位症治疗市场：公司概况

• 公司简介

U.S. Endometriosis Treatment Market Growth & Trends:

The U.S. endometriosis treatment market size is anticipated to reach USD 1,284.10 million by 2030 and is projected to grow at a CAGR of 11.86% from 2025 to 2030, according to a new report by Grand View Research, Inc. Endometriosis, characterized by the presence of tissue similar to the uterine lining outside the uterus, is increasingly recognized as a critical health concern. Affecting 2% to 10% of women aged 25 to 40 in the United States, according to Johns Hopkins Medicine, the condition imposes significant physical, emotional, and economic burdens on patients, often reducing their quality of life and limiting their participation in daily activities.

The growing prevalence of endometriosis has catalyzed demand for innovative treatments that address unmet medical needs. Pharmaceutical companies are actively developing targeted therapies to improve outcomes for affected individuals. For example, Pfizer Inc. and Myovant Sciences achieved a key milestone with the FDA approval of MYFEMBREE in August 2022, a novel oral therapy designed to treat moderate to severe pain in premenopausal women. This approval reflects the industry's commitment to addressing the specific challenges of endometriosis patients.

Public awareness campaigns also contribute significantly to market growth by emphasizing early diagnosis and timely treatment. Initiatives such as Endometriosis Awareness Month, observed annually by the New York State Department of Health, and advocacy efforts by organizations like the Endometriosis Foundation aim to educate the public and reduce stigma surrounding the condition. These campaigns underscore the severe impact of symptoms such as chronic pain, infertility, and mental health issues, encouraging patients to seek effective care.

Investments in research and development (R&D) are accelerating market expansion. Governments, private organizations, and pharmaceutical companies are dedicating significant resources to advancing endometriosis treatment. Noteworthy examples include Sunstone Life Science Ventures' USD 5.59 million investment in Forendo Pharma in 2019 for developing novel therapies, and AIMA Laboratories' USD 468.5 million funding in 2022 to innovate at-home blood-testing technologies for endometriosis diagnosis. These efforts highlight the market's potential for growth through cutting-edge therapeutic and diagnostic advancements.

Despite this progress, the market faces challenges. The widespread availability of over-the-counter (OTC) and generic drugs poses a restraint on the growth of branded pharmaceuticals. Cost-conscious patients often turn to generic medications or OTC options such as NSAIDs (e.g., aspirin, naproxen, ibuprofen) for managing pain and inflammation associated with endometriosis. These accessible and affordable alternatives are commonly chosen for mild symptoms, limiting the uptake of more advanced hormonal or surgical interventions.

Overall, the market stands at a pivotal juncture, driven by increasing disease awareness, innovation in therapeutic solutions, and robust R&D investments. While affordability concerns and competition from generics remain challenges, the market's trajectory indicates significant opportunities for stakeholders to address unmet needs and improve the lives of patients.

U.S. Endometriosis Treatment Market Highlights

• Based on treatment type, the hormone therapy segment led the market with the largest revenue share of 78.51% in 2024. Hormone therapy is the most effective and widely prescribed treatment for managing endometriosis symptoms, particularly pain and inflammation, driving its dominance in the market.
• Based on drug class, the gonadotropin-releasing hormone (GnRH) therapies segment led the market with the largest revenue share of 51.33% in 2024. GnRH therapies are highly preferred due to their targeted mechanism of action in suppressing endometrial growth, offering significant efficacy and compliance.
• Based on route of administration, the oral segment led the market with the largest revenue share of 49.14% in 2024. The oral route is favored for its convenience, ease of use, and patient adherence, making it the leading segment for endometriosis treatments.
• Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 60.99% in 2024. Retail pharmacies are the primary distribution channel due to their widespread accessibility and role in dispensing prescription medications, especially for chronic conditions like endometriosis.

Table of Contents

Chapter 1 U.S. Endometriosis Treatment Market: Methodology And Scope

• 1.1 Research Methodology
• 1.2 Research Assumptions
  • 1.2.1 Estimates And Forecast Timeline
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
  • 1.6.2 Volume Price Analysis (Model 2)
    • 1.6.2.1 Approach 2: Volume Price Analysis
    • 1.6.2.2 Revenue Modeling
• 1.7 List Of Secondary Sources
• 1.8 List Of Primary Sources

Chapter 2 U.S. Endometriosis Treatment Market: Executive Summary

• 2.1 U.S. Endometriosis Treatment Market: Market Outlook
  • 2.1.1 Market Summary
• 2.2 U.S. Endometriosis Treatment Market: Market Segmentation
• 2.3 U.S. Endometriosis Treatment Market: Competitive Insights

Chapter 3 U.S. Endometriosis Treatment Market: Industry Outlook

• 3.1 U.S. Endometriosis Treatment Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 User Perspective Analysis
• 3.3 Penetration & Growth Prospect Mapping
• 3.4 Regulatory And Reimbursement Framework
• 3.5 Market Dynamics
  • 3.5.1 Market Driver Analysis
  • 3.5.2 Market Restraint Analysis
• 3.6 U.S. Endometriosis Treatment Market Analysis Tools
  • 3.6.1 Porter's Five Forces Analysis
  • 3.6.2 Swot Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.3 Major Deals & Strategic Alliances Analysis
    • 3.6.3.1 New Product Launch
    • 3.6.3.2 Mergers And Acquisitions
    • 3.6.3.3 Expansion
    • 3.6.3.4 Partnerships
    • 3.6.3.5 Market Entry Strategies
• 3.7 U.S. Endometriosis Treatment Market Pipeline Analysis
• 3.8 U.S. Endometriosis Treatment Market Unmet Need Analysis

Chapter 4 U.S. Endometriosis Treatment Market: Competitive Landscape

• 4.1 Recent Developments And Impact Analysis, By Key Market Participants
  • 4.1.1 Ansoff Matrix
• 4.2 Company Categorization
  • 4.2.1 Innovators
  • 4.2.2 Market Leaders
• 4.3 Vendor Landscape
  • 4.3.1 List Of Key Distributors And Channel Partners
  • 4.3.2 Key Customers
• 4.4 Public Companies
  • 4.4.1 Company Market Position Analysis
  • 4.4.2 Competitive Dashboard Analysis
    • 4.4.2.1 Market Differentiators
• 4.5 Private Companies
  • 4.5.1 List Of Key Emerging Companies

Chapter 5 U.S. Endometriosis Treatment Market: Treatment Type Business Analysis

• 5.1 U.S. Endometriosis Treatment Market: Treatment Types Movement Analysis
  • 5.1.1 Pain Medication
    • 5.1.1.1 Pain Medication Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.1.2 Hormone Therapy
    • 5.1.2.1 Hormone Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 U.S. Endometriosis Treatment Market: Route Of Administration Business Analysis

• 6.1 U.S. Endometriosis Treatment Market: Route Of Administration Movement Analysis
  • 6.1.1 Oral
    • 6.1.1.1 Oral Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.1.2 Injectable
    • 6.1.2.1 Injectable Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.1.3 Others
    • 6.1.3.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 U.S. Endometriosis Treatment Market: Drug Class Business Analysis

• 7.1 U.S. Endometriosis Treatment Market: Drug Class Movement Analysis
  • 7.1.1 Nsaids
    • 7.1.1.1 Nsaids Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.1.2 Oral Contraceptive
    • 7.1.2.1 Oral Contraceptive Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.1.3 Gonadotropin Releasing Hormone
    • 7.1.3.1 Gonadotropin Releasing Hormone Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.1.4 Others
    • 7.1.4.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 U.S. Endometriosis Treatment Market: Distribution Channel Business Analysis

• 8.1 U.S. Endometriosis Treatment Market: Distribution Channel Movement Analysis
  • 8.1.1 Hospital Pharmacy
    • 8.1.1.1 Hospital Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.1.2 Retail Pharmacy
    • 8.1.2.1 Retail Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.1.3 Others
    • 8.1.3.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9 U.S. Endometriosis Treatment Market: Company Profiling

• 9.1 Company Profiles
  • 9.6.1 Bayer Ag
  • 9.6.2 Pfizer, Inc.
  • 9.6.3 Abbvie, Inc.
  • 9.6.4 Astrazeneca
  • 9.6.5 Obseva Sa
  • 9.6.6 Teva Pharmaceutical Industries
  • 9.6.7 Zydus Healthcare Limited
  • 9.6.8 Eli Lilly And Company
  • 9.6.9 Astellas Pharma Inc.

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. U.S. Endometriosis Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
• Table 4. U.S. Endometriosis Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
• Table 5. U.S. Endometriosis Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 6. U.S. Endometriosis Treatment Market, Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 U.S. Endometriosis Treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. Endometriosis Treatment Market Outlook (2021)
• Fig. 9 User perspective analysis
• Fig. 10 Penetration & growth prospect mapping
• Fig. 11 Market driver relevance analysis (Current & future impact)
• Fig. 12 Global population by age group, 2018, 2021, & 2030
• Fig. 13 General trend shifts from laboratory to point-of-care
• Fig. 14 Market restrain relevance analysis (Current & future impact)
• Fig. 15 Porter's five forces analysis
• Fig. 16 SWOT analysis, by factor (Political & legal, economic and technological)
• Fig. 17 Strategy mapping
• Fig. 18 U.S. Endometriosis Treatment market: Treatment Types outlook and key takeaways
• Fig. 19 U.S. Endometriosis Treatment market: Treatment Types movement analysis
• Fig. 20 Pain Medication market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Hormone Therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 U.S. Endometriosis Treatment market: Drug Class outlook and key takeaways
• Fig. 23 U.S. Endometriosis Treatment market: Drug Class movement analysis
• Fig. 24 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Oral Contraceptivies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Gonadotropin Releasing Hormone market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 U.S. Endometriosis Treatment market: Route of Administration movement analysis
• Fig. 29 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 U.S. Endometriosis Treatment market: Distribution Channel outlook and key takeaways
• Fig. 33 U.S. Endometriosis Treatment market: Distribution Channel movement analysis
• Fig. 34 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Retail Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Company market position analysis
• Fig. 38 Company market position analysis
• Fig. 39 Market differentiators